Cyramza (ramucirumab) / Eli Lilly, Innovent Biologics - LARVOL DELTA

Augmented antitumor activity of Tumor Treating Fields (TTFields) with anti-VEGFR and docetaxel treatment in a lung cancer mouse model (AACR 2026) - "Ramucirumab, an antibody targeting the vascular endothelial growth factor receptor (VEGFR), is approved as a second-line therapy in combination with docetaxel for metastatic NSCLC. Collectively, these findings suggest that TTFields amplify the therapeutic activity of antiangiogenic and chemotherapeutic agents by stabilizing tumor vasculature, facilitating immune cell penetration, and potentiating treatment-induced cell death."

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • PECAM1

AI-powered deep phenotyping: Vision transformers quantify vessel normalization and immune efficacy in a 3D vascularized tumor-on-a-chip (AACR 2026) - "To validate predictive utility, models were treated with FDA-approved anti-angiogenic agents (e.g., Ramucirumab, a second-line therapy for gastric cancer) and a panel of vessel normalization reagents... This AI-enabled TME platform represents a powerful New Approach Methodologies (NAMs), integrating deep learning with complex biology to perform "deep phenotyping" of the tumor microenvironment. By precisely linking vascular morphology to functional immune outcomes, it accelerates the discovery of therapies that restore the TME to a treatment-responsive state."

Clinical • Gastric Cancer • Oncology • Solid Tumor

Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC) (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Molecularly-informed prediction of treatment efficacy in the GENIE BPC NSCLC cohort using computational reasoning (AACR 2026) - "Here, we extend this analysis to the GENIE BPC NSCLC cohort to assess the broader clinical validity of DDA. From the GENIE BPC NSCLC cohort data available on Synapse, we included 1,078 patients with a single-sample genomic profile, available primary treatment data and survival outcomes (total 2,103 treatment lines, therapies included: afatinib, erlotinib, osimertinib, crizotinib, nivolumab, pembrolizumab, atezolizumab, bevacizumab+chemo, ramucirumab+chemo; and chemotherapy alone). Across a large, real-world NSCLC cohort, DDA effectively distinguished therapies with higher clinical efficacy based on the full molecular profile of each patient. These results reinforce the potential of DDA to enhance personalized treatment selection based on NGS diagnostics in precision oncology."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation (AACR 2026) - "In the resistant models, disrupting VEGFA-VEGFR2 signaling using KDR knock-out and ramucirumab treatment restored MRTX1133 sensitivity and reversed EMT in resistant cells. Inhibition of hyperactivated PI3Kγ using eganelisib, a selective p110γ inhibitor, also replicated the same results...In a mouse xenograft model of MRTX1133-resistant PANC-1 cells, anti-VEGFR2 antibody (DC101) treatment combined with MRTX1133 rechallenge more effectively reduced tumor growth and angiogenesis than either agent alone, without significant changes in body weight...Importantly, co-targeting this axis with VEGFR2 or PI3Kγ inhibitor restored sensitivity to KRAS inhibition. These findings provide a rationale for further biomarker-guided clinical trials of combined VEGFA-VEGFR2 and KRAS inhibition in patients experiencing acquired resistance after KRAS inhibitor treatment."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KDR • KRAS • PIK3CG

Tiragolumab Plus Atezolizumab and Bevacizumab in Targeted Therapy-Refractory, Immune Checkpoint Blockade-Naive, Advanced EGFR-Mutated NSCLC (IASLC-TTLC 2026) - P2 | "One patient was started on osimertinib monotherapy following disease progression on docetaxel plus ramucirumab after progression on trial therapy and developed hepatic failure resulting in death (grade 5). Accrual was halted early following termination of tiragolumab development. Interim analysis demonstrated minimal clinical efficacy of dual ICB with VEGF inhibition in TT- refractory, ICB-naïve EGFRm NSCLC. These findings suggest this combination is unlikely to represent an effective therapeutic strategy in this population."

Checkpoint block • Checkpoint inhibition • IO biomarker • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • TIGIT

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). (PubMed, Eur J Cancer) - "FOLFOXIRI plus RAM was not superior to FOLFIRI plus RAM in terms of efficacy, including ORR, in patients with untreated mCRC. Instead, first-line FOLFIRI plus RAM showed clinical efficacy and safety profiles comparable to those of doublet chemotherapy plus bevacizumab."

Journal • P2 data • Anorexia • Colorectal Cancer • Febrile Neutropenia • Hematological Disorders • Neutropenia • Oncology • Solid Tumor

Targeting vascular endothelial growth factor and its receptors in non-small cell lung cancer for improved treatment strategies. (PubMed, J Recept Signal Transduct Res) - "Anti-angiogenic therapy, for instance, with monoclonal antibodies like bevacizumab and ramucirumab, as well as multi-targeted tyrosine kinase inhibitors (TKIs) like nintedanib and anlotinib has been shown to improve the management of NSCLC. Angiogenesis-associated biomarkers, despite extensive research, have not been seen to have a clinical impact in the management and treatment of NSCLC because of the heterogeneous characteristics and the dynamic regulation of the cascade. This review summarizes current VEGF/VEGFR-targeted therapies in NSCLC, mechanisms of resistance, and future directions toward biomarker-guided therapeutic optimization."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan. (PubMed, Future Oncol) - "Nivolumab+S-1+oxaliplatin (4,104/11,276; 36.4%) was the most common first-line regimen...After first-line nivolumab was introduced for AGC in Japan, treatment patterns remained consistent with Japanese Gastric Cancer Association guidelines. Optimizing sequential therapy, including nivolumab at first-line and ramucirumab combination at second-line, may improve outcomes."

Journal • Real-world evidence • Gastric Cancer • Oncology • Solid Tumor

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. (PubMed, N Engl J Med) - P3 | "Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Adverse events were common in both groups. Events of interstitial lung disease or pneumonitis with trastuzumab deruxtecan, a known risk, were mainly low-grade. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Gastric04 ClinicalTrials.gov number, NCT04704934.)."

Journal • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2

PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. (ASCO 2025) - P3 | "Accrual was rapid, and participant representativeness enhanced in this study with pragmatic design features. Often understudied groups were better represented; the study represents a contrast with the usual better prognosis of trial populations. While RP did not improve OS, RP was not worse than SOC overall, may benefit some with SCC, and is chemotherapy-free."

Clinical • Late-breaking abstract • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study. (ASCO-GI 2026) - P2 | "Although NI was not achieved due to early closure and small sample size, FTD-TPI+RAM was relatively safe and associated with less neuropathy compared with PAC+RAM. This regimen warrants further evaluation for pts in whom neuropathy limits taxane use."

Clinical • Combination therapy • Head-to-Head • Metastases • P2 data • Esophageal Adenocarcinoma • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Association of baseline ctDNA EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinib versus osimertinib in EGFR mutant non-small cell lung cancer (AACR 2025) - P2 | "Detection of EGFR mutations from blood plasma at baseline was prognostic of clinical outcome and associated with significantly shorter PFS and OS. Detection of EGFR VAF by liquid biopsy can identify patients with higher risk of treatment progression and warrants further investigation for stratification of patients to future clinical trials."

Biomarker • Circulating tumor DNA • Clinical • Clinical data • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • KDR

Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial. (PubMed, Gastric Cancer) - "Irinotecan-based therapy offers comparable efficacy and tolerability in older and younger patients with refractory AGC."

Journal • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. (PubMed, EClinicalMedicine) - "Taiho Pharmaceutical Co. Ltd."

Biomarker • Journal • P2 data • Febrile Neutropenia • Gastric Cancer • Hematological Disorders • Neutropenia • Oncology • Pain • Solid Tumor • CAV1

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. (ASCO 2025) - P3 | "T-DXd showed statistically significant and clinically meaningful improvement in OS over RAM + PTX in pts with HER2+ unresectable/metastatic GC/GEJA, reinforcing its use as a second-line standard of care. The safety profile of T-DXd 6.4 mg/kg was consistent with the known safety profile of T-DXd in GC/GEJA, with no new safety signals."

Clinical • Late-breaking abstract • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Inflammation • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2

Efficacy and safety of trifluridine/tipiracil plus ramucirumab in advanced gastric cancer as third-line or later treatment: A multicenter phase II study. (ASCO-GI 2026) - "Background: Later-line treatment options for advanced gastric cancer (AGC), including nivolumab, irinotecan, and trifluridine/tipiracil (FTD/TPI), provide limited clinical benefit. FTD/TPI plus ramucirumab demonstrated promising efficacy and manageable toxicity as third-line or later therapy for unresectable or recurrent AGC. These findings warrant further investigation in larger, randomized studies to confirm the clinical benefits."

Clinical • Metastases • P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

First-line immuno-oncology treatment patterns in metastatic non-small cell lung cancer in Cyprus (ELCC 2026) - "Pembrolizumab was used in 93%; 11% as mono and 82% with CT. 7% received nivolumab ± ipilimumab...2L treatment was initiated in 37.5%, at a median 7.7 mo (mean 9.8 mo) from 1L initiation, mostly CT ± ramucirumab (85.3%)...HCRU reflects high metastatic disease burden/care. High percentage of males (82%), ex-/ current smokers (89%) and de novo metastatic patients (91.5%) provides rationale for prevention and screening programs."

Clinical • Immuno-oncology • IO biomarker • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC. (PubMed, JTO Clin Res Rep) - "Patients received RAM (10 mg/kg every 2 wk) plus GEF (250 mg once daily) until disease progression (period 1); patients with disease progression who acquired a T790M mutation received RAM plus osimertinib (80 mg once daily) (period 2). Treatment-emergent T790M rate post progression was 81.3%. RELAY+ revealed a favorable benefit-risk profile for RAM plus GEF in East Asian patients with untreated EGFR-mutated metastatic NSCLC, supporting RAM plus GEF as an alternative first-line treatment option, particularly in those with an L858R mutation."

Journal • Cardiovascular • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov) - P1/2 | N=210 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2026 ➔ May 2028

Trial primary completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • ERBB3 • HER-2

SWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation. (ASCO 2025) - P3 | "Lung-MAP S1800A was a Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care (SOC) for patients with NSCLC previously treated with immunotherapy that demonstrated benefit in overall survival (OS) with an improved toxicity profile over SOC. Incorporating pragmatic elements into S2302 resulted in robust accrual, increased participant representativeness and access for patients. The reduced burden on staff due to decreased data forms and elements is substantial. Pragmatic design elements should be considered as we develop trials to generalize to a broad and representative population."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update (ASCO.org) - "Twelve newly published or updated phase III randomized controlled trials met the inclusion criteria for the systematic review...Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression...For patients with pMMR/MSS HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma, trastuzumab and doublet chemotherapy is recommended; for patients with PD-L1 expression ≥1, the addition of pembrolizumab is recommended...Second-line therapy options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive gastric/GEJ adenocarcinoma, and immunotherapy for PD-L1 ≥1 esophageal squamous cell carcinoma after first-line combination chemotherapy without immunotherapy."

Clinical guideline • dMMR • MSI-H • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability

Functional drug sensitivity profiling in sarcoma using patient-derived 3D tumoroids (Sarcoma-RC 2026) - "IS exhibited a narrow yet reproducible vulnerability to gemcitabine, vinorelbine, ramucirumab and sorafenib, while most agents showed no activity. Legal entity responsible for the study The authors. Funding Marmara University."

Clinical • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor

INFORMING OVERALL SURVIVAL EXTRAPOLATION IN HEALTH TECHNOLOGY ASSESSMENT USING STRUCTURED EXPERT ELICITATION: A NICE TSD 26 CASE STUDY (ISPOR 2026) - "This case study applies National Institute for Health and Care Excellence (NICE) Decision Support Unit Technical Support Document 26 (TSD 26) guidance to elicit expert judgements of long-term survival probabilities and assesses feasibility within an HTA submission. The REVEL trial of ramucirumab plus docetaxel versus docetaxel alone in Stage IV non-small cell lung cancer was used. This work demonstrates that implementing SEE for long-term survival outcomes in line with NICE TSD 26 is feasible within HTA. Explicit consideration of hazard behaviour is critical for contextualising expert judgements and should be prioritised in SEE design. Formal elicitation of expert survival expectations can reduce uncertainty around survival model choice, supporting more robust HTA decisions and potentially improving timely patient access to effective therapies."

Case study • Clinical • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

CLARITY-Gastric 01: a randomized Phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC) (DKK 2026) - P3 | " Patients (pts) will be randomized 1:1:1 to AZD0901 dose level 1 intravenous (IV) every three weeks (Q3W; Arm 1), AZD0901 dose level 2 IV Q3W (Arm 2), or INV choice of therapy (2L: ramucirumab [ram] + paclitaxel [PTX], PTX, or docetaxel [for pts with contraindication to ram only]; 3L+: irinotecan, TAS-102 [excluding China], or apatinib [China only]; Arm 3). Previously presented at ESMO - GI Congress 2024, Final Publication Number: 495TiP, Kohei Shitara et al. Reused with permission."

Clinical • Metastases • P3 data • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • HER-2